Proteome Sciences – interims argue “confident of maintaining the good performance”. Er, where was that then?
By Steve Moore | Friday 25 August 2023
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Describing itself as “a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification”, Proteome Sciences (PRM) has announced results for the first half of the 2023 calendar year including stating that it “is confident of maintaining the good performance into the second half of the year… cash resources of £3.79m (30 June 2022: £3.20m)”. So what of a current share price response down more than 25% at 6.3p?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.